Valeant Pharmaceuticals Intl Inc. Tries to Downplay the Drug-Pricing Scandal

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been caught up in a drug-pricing scandal. What are the long-term implications for the stock?

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been hit hard by allegations of drug pricing, driving the stock down 40% over the past month. Chief Executive Officer Michael Pearson says the company plans to reduce its reliance on drugs, whose prices have been substantially raised, all the while insisting that his company has not been involved in unfair drug pricing.

“The pharmaceutical industry is being aggressively attacked for past pricing actions–not just Valeant, but all companies,” Pearson said in a conference call following the company’s latest earnings report. “Given the environment, the pricing that pharmaceutical companies will take in will be more modest,” he added, suggesting a maximum 10% increase in the future.

The company said that during the next 12 months it will consider selling or privatizing its neurology and “other” drug categories, in which much of the “mispriced” buying has occurred; it’s a small part of Valeant’s business, according to Pearson.

Evercore ISI analyst Umer Raffat said because the drugs in question represent only about 10% of Valeant’s revenues, his outlook for the company remains unchanged. “If you take out neuro and ‘other’, which they may potentially divest, it actually makes the volume price even lesser to the overall business,” he said in a note to clients. “It’s not a big part of their business, and that’s the most important thing.”

So, why is the stock dropping like a stone? Well, even though the company insists its involvement in the drug-pricing scandal is minimal, the U.S. Attorney’s offices in Massachusetts and New York have issued court orders forcing Valeant to turn over documents tied to the U.S. price hikes of two heart drugs.

In the U.S. prices for Nitropress and Isuprel increased by 212% and 525% after the company acquired the rights to sell them. Despite Pearson’s attempts to soothe the market, investors hate uncertainty, and that’s just what this scandal has produced.

This week CIBC World Markets cut its price target on the U.S. version of the stock to $200 from $275, citing the company’s statement that the price of drugs will moderate.

The scandal overwhelmed Valeant’s mainly positive earnings for the third quarter, which were released on Monday. The company’s net income rose to $2.74 per share in the third quarter, up from $2.11 in the third quarter of 2014. Revenue rose to $2.78 billion, just above estimates of $2.77 billion.

The problem for Valeant is that even if it has cleaned up its act over drug pricing, the story could remain high profile as it wends its way through the U.S. court system. For long-term investors, this could be a buying opportunity. But it comes with risk if the courts ultimately sanction Valeant.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Doug Watt has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Target. Stand out from the crowd

2 Canadian Stocks I’m Buying Lots of This Year

I’m looking to snatch up exciting Canadian stocks like VieMed Healthcare Inc. (TSX:VMD) throughout 2023.

Read more »

grow money, wealth build
Dividend Stocks

Got $3,000? 3 TSX Growth Stocks to Buy in January 2023

Top TSX growth stocks that look appealing for 2023.

Read more »

woman data analyze
Dividend Stocks

Need Passive Income? Turn $15,000 Into $851 Annually

This passive-income stock is already climbing higher, up 16% in the last three months! Yet it's still valuable, so you…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

Retirees: 3 Reliable Canadian Dividend Stocks to Buy Now for Passive Income

Top TSX dividend stocks now appear oversold.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.

2 TSX Stocks Safer for Investing in a Recession

These consumer companies will likely beat the broader market averages amid a recession. These stocks offer stability, income, and consistent…

Read more »

Dividend Stocks

For $100 in Passive Income Each Month, Buy 1,500 Shares of This REIT

REITs such as Northwest Healthcare can enable investors create a passive-income stream as well as benefit from capital gains.

Read more »

A colourful firework display
Dividend Stocks

2 Canadian Growth Stocks (With Dividends) to Start 2023 With a Bang

Here are two of the best dividend-paying Canadian growth stocks you can invest in at the start of 2023 and…

Read more »

sale discount best price
Dividend Stocks

4 Insanely Cheap Canadian Stocks to Buy for Passive Income

The recent bear market has created some incredible bargains, especially for those looking for passive income. Here are four cheap…

Read more »